PARP1 — Drug Target

All drugs that target PARP1 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

PARP inhibitor

Phase 2 pipeline (1)

• Arm A - Olaparib · GERCOR - Multidisciplinary Oncology Cooperative Group · PARP inhibitor · Oncology
  Olaparib is a PARP inhibitor that blocks the enzyme PARP1, preventing cancer cells from repairing DNA damage.